TAMPA, Fla.--(BUSINESS WIRE)--The Moffitt Cancer Center today said findings from a clinical trial presented at the American Society of Clinical Oncology (ASCO) meeting evaluating REVLIMID (lenalidomide) as a monotherapy is both effective and well-tolerated in patients who have been previously treated for multiple myeloma with two or more therapies.
